Research programme: cancer immunotherapeutics - GlobeImmune

Drug Profile

Research programme: cancer immunotherapeutics - GlobeImmune

Alternative Names: GI-10000; GI-10001; GI-3000; GI-3001; GI-6200

Latest Information Update: 18 May 2016

Price : $50

At a glance

  • Originator GlobeImmune
  • Developer Celgene Cellular Therapeutics; GlobeImmune
  • Class Yeasts
  • Mechanism of Action Epidermal growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 20 Apr 2009 Preclinical development of the GI 3000 and GI 10000 programmes is ongoing in the US
  • 19 Apr 2009 Preclinical pharmacodynamics data in Cancer presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR-2009)
  • 29 Oct 2007 Data presented at the 19th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2007) added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top